Reproducibility of the New Indicator Test for Sudomotor Function (Neuropad®) in Patients with Type 2 Diabetes Mellitus: Short Communication

Abstract

The aim of this study was to examine the reproducibility of the new indicator test for sudomotor function (Neuropad®) in type 2 diabetic patients. The study included 142 type 2 diabetic patients (70 men) with a mean age of 67.3 ± 7.6 years and a mean diabetes duration of 14.2 ± 6.3 years. Sudomotor function was assessed by means of colour change in the indicator test. Each patient was examined twice. Moreover, inter-observer variability was assessed in 60 patients (35 patients with sudomotor dysfunction, 25 patients without sudomotor dysfunction). In the right foot, a highly significant (r = 0.91, p = 0.001) correlation was observed between time until complete colour change of the test on the first (910.7 ± 431.6 seconds) and second examination (935.8 ± 440.1 seconds). In the left foot, a highly significant (r = 0.89, p = 0.001) correlation was observed between time until complete colour change of the test on the first (911.6 ± 430.3 seconds) and second examination (940.5 ± 441.2 seconds). Reproducibility was excellent both in patients with sudomotor dysfunction (p = 0.001) and in those without sudomotor dysfunction (p = 0.001). Agreement in diagnosis of sudomotor dysfunction between the two examinations was 98 %. Inter-observer reproducibility was excellent (p = 0.001), both in patients with sudomotor dysfunction and in those without sudomotor dysfunction. Intra- and interobserver Coefficient of Variance ranged between 4.1 % and 5.1 %. Conclusions: These results indicate that reproducibility of the new indicator test for sudomotor function is excellent in type 2 diabetic patients with or without sudomotor impairment.

Key words

Diabetes mellitus - diabetic peripheral neuropathy - diabetic foot - sudomotor dysfunction

References

• 1 American Diabetes Association and American Academy of Neurology . Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy.  Diabetes. 1988;  37 1000-1004
• 2 Bax G, Fagherazzi C, Piarulli F, Nicolucci A, Fedele D. Reproducibility of Michigan Neuropathy Screening Instrument (MNSI).  Diabetes Care. 1996;  19 904-905
• 3 Boulton A JM, Gries F A, Jervell J. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy.  Diabet Med. 1998;  15 508-514
• 4 Boulton A JM, Kirsner R S, Vileikyte L. Neuropathic diabetic foot ulcers.  N Engl J Med. 2004 a;  351 48-55
• 5 Boulton J AM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture.  Diabetologia. 2004 b;  47 1343-1353
• 6 Budavari S, O'Neil M J, Smith A, Heckelman P E, Kinneary (eds) J F. The Merck Index. An Encyclopaedia of Chemicals, Drugs and Biologicals. 12th edn. New Jersey; Merck Research Laboratories 1996: 2503
• 7 Duby J J, Campbell R K, Setter S M, White J R, Rasmussen K A. Diabetic neuropathy: an intensive review.  Am J Health Syst Pharm. 2004;  61 160-173
• 8 Edmonds M E. The diabetic foot, 2003.  Diabetes Metal Res Rev. 2004;  20 (Suppl 1) S9-S12
• 9 Kempler P. Autonomic neuropathy: a marker of cardiovascular risk.  Br J Diabetes Vasc Dis. 2003;  3 84-90
• 10 La Cava E C. Your nerves. Neuropathy affects more than 50 percent of people with diabetes. Here's what you can do to prevent it.  Diabetes Forecast. 2002;  55 67-69
• 11 Low P A. Sudomotor function. Gries FA, Low PA, Cameron NE, Ziegler D Textbook of Diabetic Neuropathy. Stuttgart; Georg Thieme Verlag 2003: 274-278
• 12 Papanas N, Papatheodorou K, Christakidis D, Papazoglou D, Giassakis G, Piperidou H, Monastiriotis C, Maltezos E. Evaluation of a new indicator test for sudomotor function (Neuropad®) in the diagnosis of peripheral neuropathy in type 2 diabetic patients.  Exp Clin Endocrinol Diabetes. 2005;  113 1-4
• 13 Perkins B A, Bril V. Diabetic neuropathy: a review emphasizing diagnostic methods.  Clin Neurophysiol. 2003;  114 1167-1175
• 14 Petit Jr W A, Upender R P. Medical evaluation and treatment of diabetic peripheral neuropathy.  Clin Pediatr Med Surg. 2003;  20 671-688
• 15 Reiber G E, Vileikyte L, Boyko E J, del Aguila M, Smith D G, Lavery L A, Boulton A JM. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings.  Diabetes Care. 1999;  22 157-162
• 16 Valensi P, Attali J R, Gagant S. Reproducibility of parameters for assessment of diabetic neuropathy. The French Group for Research and Study of Diabetic Neuropathy.  Diabet Med. 1993;  10 933-939
• 17 Vinik A I, Maser R E, Mitchell B D, Freeman R. Diabetic autonomic neuropathy: Technical review.  Diabetes Care. 2003;  26 1553-1579
• 18 Young J A. Cobalt (II) chloride hexahydrate.  J Chem Edu. 2003;  80 610
• 19 Zick R, Schäper T, Deeters U. Periphere diabetische Neuropathie. Die Schweißsekretion am Fuß messen.  Klinikarzt. 2003;  32 192-194